Celltrion Pharm announces vision to become ‘Top 5'

After deciding not to merge with its Celltrion

Established growth strategy for manufacturing, research, and sales... Will diversify revenue streams to provide a foundation for high growth

“Seek sustainable growth by growing into a Global CMO+accelerating R&D+licensing-out+product expansions”

On the 19th, Celltrion Pharm announced its 'Vision 2030,’ which outlines the company’s vision to become one of the top five pharmaceutical companies in Korea by 2030.

 

Until recently, Celltrion Pharm was promoting a merger with Celltrion, but the plan was reviewed again due to shareholder opposition, upon which the final decision was made not to merge on the 16th.

 

Vision 2030 is the first mid- to long-term established for Celltrion Pharm since the cancellation of the merger.

 

In Vision 2030, Celltrion Pharm presented detailed projects for each of the following sectors: ▲manufacturing, ▲R&D, and ▲sales as a comprehensive pharmaceutical company that manufactures and sells chemical and biological drugs.

 

In manufacturing, the company will expand its production capacity around its core facility, its Cheongju Plant.

 

The Cheongju plant is the company’s core production base for chemical drugs and has obtained GMP certification from international organizations including the United States, Europe, Japan, and Brazil.

 

It also has an annual production capacity of 16 million prefilled syringes (PFS).

 

The company plans to accelerate its growth by gradually increasing the proportion of PFS-type biopharmaceuticals that the company has started full-scale commercial production this year.

 

To preemptively respond to the rapidly growing demand for PFS formulations, the company plans to build an additional production line utilizing its 13,500㎡ spare lands at its Cheongju plant.

 

Upon completion of the expansion, the company’s production capacity will increase up to threefold.

 

The company is also planning to expand its global CMO business.

 

In the R&D sector, Celltrion Pharm plans to strengthen its capabilities by adding specialized personnel and developing ADC (antibody-drug conjugate) anticancer drugs and new drug platform technologies in earnest.

 

To this end, Celltrion Pharm raised the status of its R&D organization in Cheongju last year to report directly to the CEO.

 

It also expanded and reorganized the organization and relocated it to the Songdo Global Biotech Research Center in Songdo, Incheon.

 

Through the reorganizations, Celltrion Pharm plans to become a drug development company that develops not only new drug platform technologies but also innovative new drugs to increase sales by licensing out technologies.

 

In sales, the company will actively expand the range of its chemical and biological drug products.

 

It plans to significantly expand the production of its biosimilar products, from the 6 it currently produces, including Celltrion's 'Remsima' and ‘Yuflyma,’ to a total of 22 products by 2030.

 

The launch of its autoimmune disease treatment 'Stekima', eye disease treatment ‘Eydenzelt,’ and allergic asthma treatment ‘Omlyclo,’ which have received domestic approval, is also imminent.

 

In the case of chemical drugs, the company's strategy is to secure additional high-value-added products through in-house development and active licensing-in activities and to expand its product portfolio to gain differentiated competitiveness.

 

An official from Celltrion Pharm said, “We have achieved about twofold growth in sales over the past 5 years with even growth across all our business segments.

 

As a comprehensive pharmaceutical company with a diversified portfolio and sales structure, we aim to continue this growth trend and do our best to achieve our goal of becoming one of the top five domestic companies by 2030.”